Bioequivalence evaluation of two different formulations of ciprofloxacin tablets in healthy volunteers

Singapore Medical Journal

Volumn 48, Issue 9, 2007, Pages 819-823

  Hassan, Yahaya ^a   Alfadly, S O ^b   Azmin, M N ^c   Peh, K K ^c   Tan, T F Y ^c   Noorizan, A A ^b   Ismail, O ^d  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b Clinical Pharmacy Programme

^c Department of Pharmaceutical Technology ^*

^d Penang Adventist Hospital   (Malaysia)

Author keywords

Bioequivalence; Ciprofloxacin; Healthy volunteers; High performance liquid chromatographic analysis; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LOGLINEAR MODEL; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TABLET FORMULATION; ULTRAVIOLET RADIATION; MALE; PHARMACOKINETICS; REFERENCE VALUE; TABLET;

ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; REFERENCE VALUES; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 35848944353     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schulz HU, Steinijans VW. Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol Ther Toxicol 1991; 29:293-8.
2. Campoli-Richards DM, Monk JP, Price A, et al. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988; 35:373-447.
3. Carlucci G. Analysis of fluoroquinolones in biological fluids by highperformance liquid chromatography. J Chromatogr A 1998; 812:343-67.
4. Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19:434-61.
5. Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability of drugs. Drugs 1996; 51:1019-74.
6. Fabre D, Bressolle F, Gomeni R, et al. Steady-State pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: Penetration of the bronchial mucosa. Antimicrob Agents Chemother 1991; 35:2521-5.
7. Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy (Basel) 1990; 36:77-84.
8. Galicia I, Frias-Iniesta J, Carcas AJ, et al. Bioequivalence evaluation of 2 different oral formulations of ciprofloxacin in healthy volunteers. Int J Clin Pharmacol Ther 1998; 36:282-5.
9. Shah VP, Midha KK, Dighe S, et al. Conference report: analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 1991; 16:249-55.
10. Gilbaldi M, Perrier D. Absorption kinetics and bioavailability. In: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982: 145-95.
11. Wagner JG. Statistics. In: Fundamentals of Clinical Pharmacokinetics. 1st ed. Hamilton IL: Drug Intelligence Publications, 1975: 285-305.
12. Chow CS, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker, 2000: 1.
13. Abdallah RM, Alam SM, Awaad FM, et al. Bioequivalence of two brands of ciprofloxacin 750mg tablets (Sarf and Ciprobay) in healthy human volunteers. Drug Dev Ind Pharm 2002; 28: 423-9.
14. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Working Group on the Efficacy of Medicinal Products. London, 2001. Available at: emea.europe.eu/pdfs/ human/ewp/140198en.pdf. Accessed October 10, 2005.
15. Westlake WJ. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci 1972; 61:1340-1.
16. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991; 29:1-8.